相关实验视频

Updated: Jul 2, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

用于治疗T细胞工程的非病毒性RNA输送

Dominika Berdecka¹, Stefaan C De Smedt², Winnok H De Vos³

¹Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.

Advanced drug delivery reviews

|February 24, 2024

概括

非病毒RNA输送提供了一个更安全,更通用的替代方案,用于在采用细胞治疗中工程T细胞,克服病毒载体的局限性,以改善癌症治疗. 这种方法可以增强T细胞的功能,从而获得更好的治疗结果.

科学领域:

免疫学免疫学免疫学
生物技术是生物技术.
在瘤学瘤学.

背景情况:

采用T细胞疗法,特别是使用仿真抗原受体 (CAR) 工程T细胞,在血液癌症中是成功的,但在固体瘤中是有限的.
目前的工程T细胞制造依赖于病毒载体,面临安全,成本和监管挑战.
病毒载体的限制需要探索替代的,更可持续的T细胞工程策略.

研究的目的:

审查采用T细胞治疗的非病毒性RNA输送方法.
为突出RNA疗法和制造业的进步.
讨论将RNA输送到T细胞中的挑战和技术.

主要方法:

对RNA治疗类型和制造进步的概述.
讨论T细胞RNA输送方面的挑战.
探索当前和新兴的非病毒RNA传递技术.
对RNA修饰的T细胞进行的临床前和临床研究的综述.

主要成果:

非病毒传递方法,包括膜透和载体介导方法,提供了多功能性和可持续性.
RNA输送允许对T细胞表型和功能的受控调节.
目前正在开发各种技术,以有效地将RNA输入T细胞.

结论:

非病毒RNA输送是克服T细胞工程中的病毒载体局限性的有希望的策略.
这种方法有可能推进采用T细胞疗法,特别是在固体瘤中.
进一步的研究和临床研究正在进行中,以优化RNA修饰的T细胞疗法.

关键词:

癌症免疫疗法癌症免疫疗法细胞工程是细胞工程.细胞疗法是一种细胞疗法.基因治疗是一种基因疗法.非病毒性传递是非病毒性传递.对于RNA疗法来说,它是非常重要的.一个T细胞细胞.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Small RNA Transfection in Primary Human Th17 Cells by Next Generation Electroporation

Small RNA Transfection in Primary Human Th17 Cells by Next Generation Electroporation

Published on: April 13, 2017

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...